[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine].
To assess the anti-arrythmic effect of L-carnitina, propafenone and mexiletine, we tested the drugs in 50 patients with effort angina and ventricular ectopic beats (VEB). The patients were randomized in 5 groups: Group A: was treated with oral L-carnitine at the dose of 2 g x 3 for two weeks. Group B: oral propafenone at the dose of 300 mg x 3 for two weeks. Group C: as group B+L-carnitine+g x 3 at the second weeks. Group D: oral mexiletine at the dose of 200 mg x 3 for two weeks. Group E: as group D+L-carnitine 2 gr x 3 at the second week. After 7 and 14 days of treatment, in all patients an Holter examination was performed. Our results show that L-carnitine exerts a significant reduction of the VEB and its administration potentiates the anti-arrythmic effect of propafenone and mexiletine.
Mondillo
S
S
Istituto di Patologia Speciale Medica, Università degli Studi di Siena.
Faglia
S
S
D'Aprile
N
N
Mangiacotti
L
L
Campolo
M A
MA
Agricola
E
E
Palazzuoli
V
V
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D002331:Carnitine / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000627:therapeutic use*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications* / Q000503:physiopathology; D011405:Propafenone / Q000627:therapeutic use*; D018879:Ventricular Premature Complexes / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D011405:Propafenone; D002331:Carnitine
Terapia delle aritmie indotte da ischemia miocardica. Associazione di L-carnitina e propafenone e mexiletina.